Non-transferable risk: Difference between revisions
From ACT Wiki
Jump to navigationJump to search
imported>Doug Williamson (Link with Committed risk and Uncommitted risk pages) |
imported>Doug Williamson (Layout.) |
||
| Line 2: | Line 2: | ||
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate. In the case of non-transferable business risks (which by definition are not avoided) it is important that the firm has a distinctive competence in the relevant areas. | Non-transferable risks might be avoided or accepted and retained or reduced as appropriate. | ||
In the case of non-transferable business risks (which by definition are not avoided) it is important that the firm has a distinctive competence in the relevant areas. | |||
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted. | For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted. | ||
Revision as of 14:10, 21 May 2015
Non-transferable risks are risks which must be borne by an organisation.
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate.
In the case of non-transferable business risks (which by definition are not avoided) it is important that the firm has a distinctive competence in the relevant areas.
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted.
